Income statement
USD
Annual
| Metric | 2005 | 2004 | 2003 | 2002 | 2001 |
|---|---|---|---|---|---|
| Revenue | 1M | 1M | 2M | 2M | 688K |
| Gross Profit | -69K | -318K | 316K | 1M | 688K |
| Operating Income | 5M | 6M | 2M | 2M | 3M |
| EBITDA | -5M | -6M | -2M | -2M | -2M |
| Net Income | -5M | -6M | -2M | -2M | -3M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.0001
+0.00% today
1Y Change
+0.00%
Window
Jun 23, 2025 → Jun 17, 2026
Coverage: 248 bars · Jun 23, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Vasamed, Inc. (VSMD) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 0.0% across the available one-year price window (Jun 23, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of +29.7%, EPS growth of +29.2%, a dividend yield of 0.0%. What stands out right now is revenue +29.7%, EPS +29.2%, free cash flow -21.5% with operating margin 342.1% and ROIC 742.8%. Valuation is more restrained than many high-expectation growth names at price/sales 0.0. Overall, the current profile looks closer to a quality compounder than a generic broad-market placeholder. Stock Foundry combines VSMD price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VSMD
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
VSMD Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for VSMD and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$687.5K
-56.3% YoY
FY Net Income
-$3.4M
-83.5% YoY
Free Cash Flow
-$1.2M
+49.8% YoY
Revenue Growth
+29.7%
EPS Growth
+29.2%
Gross Margin
-5.0%
Net Margin
-352.6%
Income statement
USD
| Metric | 2005 | 2004 | 2003 | 2002 | 2001 |
|---|---|---|---|---|---|
| Revenue | 1M | 1M | 2M | 2M | 688K |
| Gross Profit | -69K | -318K | 316K | 1M | 688K |
| Operating Income | 5M | 6M | 2M | 2M | 3M |
| EBITDA | -5M | -6M | -2M | -2M | -2M |
| Net Income | -5M | -6M | -2M | -2M | -3M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2005 | 2004 | 2003 | 2002 | 2001 |
|---|---|---|---|---|---|
| Cash & Equivalents | 1K | 9K | 17K | 244K | 665K |
| Total Assets | 2M | 1M | 2M | 3M | 2M |
| Total Liabilities | 1M | 5M | 610K | 3M | 2M |
| Shareholder Equity | 595K | -4M | 1M | -299K | -193K |
| Total Debt | 23K | 0 | 0 | 0 | 1M |
| Net Debt | 22K | -9K | -17K | -244K | 824K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
1M
+46.1% YoY
Capital Expenditures
10K
+94.6% YoY
Free Cash Flow
1M
+49.8% YoY
Key ratios
Gross Margin
-5.0%
Operating Margin
342.1%
Net Margin
-352.6%
ROE
315.4%
Debt / Equity
0.04x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.